A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

This study has been completed.
Information provided by (Responsible Party):
Esperion Therapeutics
ClinicalTrials.gov Identifier:
First received: December 14, 2012
Last updated: August 19, 2013
Last verified: August 2013

This study will assess the safety, atorvastatin pharmacokinetics, and LDL-C lowering efficacy of ETC-1002 versus placebo in hypercholesterolemic subjects on background therapy of atorvastatin 10 mg.

Condition Intervention Phase
Drug: ETC-1002
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug Interaction Study to Evaluate the Safety, Tolerability and Effect on Atorvastatin Pharmacokinetics of ETC-1002 Added to Atorvastatin 10 mg/Day in Subjects With Hypercholesterolemia

Resource links provided by NLM:

Further study details as provided by Esperion Therapeutics:

Primary Outcome Measures:
  • Area under the plasma concentration versus time curve (AUC) of atorvastatin and its active metabolites [ Time Frame: 4 and 8 weeks ] [ Designated as safety issue: No ]
  • Peak plasma concentration (Cmax) of atorvastatin and its active metabolites [ Time Frame: 4 and 8 weeks ] [ Designated as safety issue: No ]
  • Number of subjects with adverse events, clinical lab abnormalities and other safety findings [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Percent change in LDL-C [ Time Frame: 2, 4, 6 and 8 weeks ] [ Designated as safety issue: No ]
  • Percent change in other lipids and cardio-metabolic risk factors [ Time Frame: 2, 4, 6 and 8 weeks ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Area under the plasma concentration versus time curve (AUC) and peak plasma concentration (Cmax) of ETC-1002 and its active metabolite [ Time Frame: 4 and 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 58
Study Start Date: December 2012
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ETC-1002 Drug: ETC-1002
Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • For subjects on current daily statin therapy - LDL-C 100-220 mg/dL and triglycerides <350 mg/dL (prior to switching to sponsor -provided atorvastatin 10 mg/day and stopping all other lipid-regulating drugs and supplements) at the S1 Visit,
  • For subjects not on current daily statin therapy - LDL-C ≥ 110 mg/dL and ≤ 220 mg/dL

Exclusion Criteria:

  • Acute significant cardiovascular disease
  • Uncontrolled hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01779453

United States, Indiana
Indianapolis, Indiana, United States, 46260
United States, Kentucky
Louisville, Kentucky, United States, 40213
United States, Virginia
Richmond, Virginia, United States, 23294
Sponsors and Collaborators
Esperion Therapeutics
Study Director: Noah Rosenberg, MD Esperion Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: Esperion Therapeutics
ClinicalTrials.gov Identifier: NCT01779453     History of Changes
Other Study ID Numbers: 1002-007
Study First Received: December 14, 2012
Last Updated: August 19, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Esperion Therapeutics:
Drug-drug interaction
Combination therapy

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on August 27, 2015